Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Biological E. Limited - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Biological E. Limited - Product Pipeline Review - 2014', provides an overview of the Biological E. Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Biological E. Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Biological E. Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Biological E. Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Biological E. Limited's pipeline products Reasons to buy - Evaluate Biological E. Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Biological E. Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Biological E. Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Biological E. Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biological E. Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Biological E. Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Biological E. Limited Snapshot 5 Biological E. Limited Overview 5 Key Information 5 Key Facts 5 Biological E. Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Biological E. Limited - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Biological E. Limited - Pipeline Products Glance 14 Biological E. Limited - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Biological E. Limited - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Biological E. Limited - Unknown Stage Pipeline Products 16 Unknown Products/Combination Treatment Modalities 16 Biological E. Limited - Drug Profiles 17 DTwP-HBV-Hib 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 DTwP-IPV 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 haemophilus influenzae [serotype B] vaccine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 meningococcal [serotypes A, C, W, Y] vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 rotavirus vaccine (tetravalent) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Vaccine for Dengue 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 DTwP + Hib 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 DTwP-Hep B-IPV-Hib 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 DTwP-IPV + Hib 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Hep B-IPV-Hib 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Biological E. Limited - Pipeline Analysis 27 Biological E. Limited - Pipeline Products by Target 27 Biological E. Limited - Pipeline Products by Route of Administration 28 Biological E. Limited - Pipeline Products by Molecule Type 29 Biological E. Limited - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Biological E. Limited, Key Information 5 Biological E. Limited, Key Facts 5 Biological E. Limited - Pipeline by Indication, 2014 7 Biological E. Limited - Pipeline by Stage of Development, 2014 9 Biological E. Limited - Monotherapy Products in Pipeline, 2014 10 Biological E. Limited - Combination Treatment Modalities in Pipeline, 2014 11 Biological E. Limited - Partnered Products in Pipeline, 2014 12 Biological E. Limited - Partnered Products/ Combination Treatment Modalities, 2014 13 Biological E. Limited - Phase III, 2014 14 Biological E. Limited - Preclinical, 2014 15 Biological E. Limited - Unknown, 2014 16 Biological E. Limited - Pipeline by Target, 2014 27 Biological E. Limited - Pipeline by Route of Administration, 2014 28 Biological E. Limited - Pipeline by Molecule Type, 2014 29 Biological E. Limited, Other Locations 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.